8-K: Intensity Therapeutics Receives Nasdaq Delisting Warning Due to Minimum Bid Price Non-Compliance

Intensity Therapeutics, Inc. has received a notice from Nasdaq regarding its failure to maintain the minimum $1.00 closing bid price requirement, initiating a 180-day grace period to regain compliance.

Summary

• On June 6, 2025, Intensity Therapeutics, Inc. (INTS) received a letter from The Nasdaq Stock Market (Nasdaq) notifying the company of non-compliance with Nasdaq Listing Rule 5550(a)(2).
• The non-compliance stems from the company's common stock not maintaining a minimum closing bid price of $1.00 per share for the preceding 30 consecutive business days.
• This notice does not immediately affect the listing or trading of INTS common stock, which will continue to trade on The Nasdaq Capital Market.
• The company has a grace period of 180 calendar days, until December 3, 2025, to regain compliance.
• Compliance can be achieved if the closing bid price is at or above $1.00 for a minimum of 10 consecutive business days during this 180-day period.
• If compliance is not met by December 3, 2025, the company may be eligible for additional time if it meets other listing standards (excluding the bid price) and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
• Nasdaq may issue a delisting notice if it appears the company cannot cure the deficiency or is otherwise ineligible for an extension, which the company would then be entitled to appeal.

Sentiment

Score: 3

Explanation: The document reports a negative event (Nasdaq non-compliance notice) which indicates a significant challenge for the company's stock listing and market perception, despite the existence of a grace period.

Positives

• The notice has no immediate effect on the listing or trading of the company's common stock.
• The company has a grace period of 180 calendar days, until December 3, 2025, to regain compliance.
• The company may be eligible for additional time to comply if certain conditions are met after the initial grace period.

Negatives

• The company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
• Failure to regain compliance could lead to delisting from The Nasdaq Capital Market.
• A potential reverse stock split may be necessary to regain compliance, which can be dilutive or negatively perceived by investors.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to regain compliance with the Minimum Bid Price Requirement.
• No assurance that the company will be able to regain compliance within the grace period or any potential extension.
• Potential need for a reverse stock split, which carries its own risks regarding investor perception and share liquidity.
• Risk that Nasdaq may not grant a further extension of time to regain compliance.

Future Outlook

Intensity Therapeutics intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement. However, there is no assurance that the company will be able to regain compliance or that Nasdaq will grant a further extension.

Management Comments

• Lewis H. Bender, Chief Executive Officer, signed the report, indicating the company's official acknowledgment and reporting of the Nasdaq notice.

Industry Context

Receiving a minimum bid price non-compliance notice is a common occurrence for smaller, often pre-revenue, biotechnology companies listed on Nasdaq, as their stock prices can be volatile and susceptible to market sentiment and clinical trial progress. Such notices highlight the financial pressures and market valuation challenges faced by companies in this sector.

Stakeholder Impact

• Shareholders face potential dilution if a reverse stock split is implemented to regain compliance.
• Shareholders face the risk of delisting, which could significantly impact the liquidity and valuation of their shares.
• The notice may negatively impact investor confidence and the company's ability to raise future capital.

Next Steps

• Intensity Therapeutics will actively monitor the bid price of its common stock.
• The company will consider available options to regain compliance with the Minimum Bid Price Requirement.
• If compliance is not achieved by December 3, 2025, the company may need to meet additional listing requirements and notify Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split.
• If delisting is determined, the company would be entitled to appeal the determination to a Nasdaq hearings panel.

Key Dates

Recommendation

Keywords

Intensity Therapeutics, INTS, Nasdaq, Delisting Notice, Minimum Bid Price, Listing Compliance, Reverse Stock Split, Biotechnology, Pharmaceuticals